Related Experiment Video

Updated: May 6, 2026

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence
10:52

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence

Published on: December 23, 2022

7.8K

Decline in platelet count after percutaneous transcatheter closure of congenital heart disease

Daxin Zhou1, Xiaochun Zhang, Wenzhi Pan

  • 1Dept. of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.

Acta Cardiologica
|November 6, 2013
PubMed

Insights

Decline in platelet count (DPC) is common in congenital heart disease (CHD) patients after percutaneous transcatheter closure (PTC). This DPC is linked to more bleeding and longer hospital stays, especially in patent ductus arteriosus cases.

Area of Science:

  • Cardiology
  • Hematology

Background:

  • Congenital heart disease (CHD) is a common condition requiring interventions.
  • Percutaneous transcatheter closure (PTC) is a minimally invasive procedure used to treat certain CHD defects.
  • Decline in platelet count (DPC) following PTC in CHD patients is not well-documented.

Purpose of the Study:

  • To determine the incidence and severity of DPC in patients with CHD undergoing PTC.
  • To identify predictors of severe DPC in this patient population.
  • To assess the clinical implications of DPC, including bleeding events and hospital stay.

Main Methods:

  • A consecutive series of 336 patients with CHD undergoing PTC were enrolled.
  • Platelet counts were monitored daily for at least 5 days post-procedure.
  • Bleeding events and other clinical outcomes were systematically observed.

Main Results:

  • A significant proportion of patients (29.2%) experienced DPC, with 6.3% having severe DPC (>50% drop).
  • Severe DPC was associated with longer hospital stays (8.4 vs. 4.4 days) and a higher rate of minor bleeding (42.9%).
  • Independent predictors of severe DPC included occluder size, residual shunts, and specific CHD types, with patent ductus arteriosus (PDA) showing the highest risk (12.6%).

Conclusions:

  • DPC is a frequent complication in CHD patients undergoing PTC.
  • Severe DPC correlates with increased minor bleeding and prolonged hospitalization.
  • PDA closure using large occluders and in the presence of residual shunts poses the highest risk for developing DPC.
Abstract

More Related Videos

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

19.4K
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.3K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
14.5K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
7.3K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K